Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.
- DOI
- 10.1186/s13045-020-01004-y
- Published
- 2021 Feb 24
- Container
- Journal of hematology & oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s13045-020-01004-y,
title = {Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.},
author = {Kreitman RJ and Dearden C and Zinzani PL and Delgado J and Robak T and le Coutre PD and Gjertsen BT and Troussard X and Roboz GJ and Karlin L and Gladstone DE and Kuptsova-Clarkson N and Liu S and Patel P and Rotolo F and Mitry E and Pastan I and Giles F and Study 1053 investigators},
year = {2021},
journal = {Journal of hematology \& oncology},
doi = {10.1186/s13045-020-01004-y},
url = {https://doi.org/10.1186/s13045-020-01004-y}
}RIS
TY - JOUR TI - Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. AU - Kreitman RJ AU - Dearden C AU - Zinzani PL AU - Delgado J AU - Robak T AU - le Coutre PD AU - Gjertsen BT AU - Troussard X AU - Roboz GJ AU - Karlin L AU - Gladstone DE AU - Kuptsova-Clarkson N AU - Liu S AU - Patel P AU - Rotolo F AU - Mitry E AU - Pastan I AU - Giles F AU - Study 1053 investigators PY - 2021 JO - Journal of hematology & oncology DO - 10.1186/s13045-020-01004-y UR - https://doi.org/10.1186/s13045-020-01004-y ER -
APA
RJ, K., C, D., PL, Z., J, D., T, R., PD, L. C., BT, G., X, T., GJ, R., L, K., DE, G., N, K., S, L., P, P., F, R., E, M., I, P., F, G., & investigators, S. 1. (2021). Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.. Journal of hematology & oncology. https://doi.org/10.1186/s13045-020-01004-y
Source records
- pubmed · retrieved 2026-09-26T21:23:56.000Z